Abstract
Vitamin D, beyond its classical roles in the regulation of calcium and phosphorus homeostasis and bone metabolism, has been implicated in multiple pathological processes, including progression from inflammation to cancer development and also involvement in autoimmune diseases as well as cardiovascular disorders. In this review, we shall discuss the different roles of vitamin D and its therapeutic targets in different gastrointestinal diseases, focusing on colorectal cancer (CRC) and inflammatory bowel disease (IBD). To this end, vitamin D deficiency has been identified as a risk factor of CRC. On the other hand the active metabolite of vitamin D, 1, 25- dihydroxyvitamin D3 (1, 25(OH)2D3) has multiple anti-cancerous benefits including inhibition of proliferation, induction of apoptosis, promotion of differentiation and suppression of angiogenesis in tumors. In IBD, vitamin D is involved in the pathogenic process through the normalization of immune responses in the colon. With these experimental findings, well-designed and large-scale clinical trials are warranted to further define the therapeutic action of vitamin D in the prevention and/or treatment of IBD and further on CRC in humans.
Keywords: Cancer, colon, inflammation, vitamin D.
Current Pharmaceutical Design
Title:The Current Role and Therapeutic Targets of Vitamin D in Gastrointestinal Inflammation and Cancer
Volume: 21 Issue: 21
Author(s): Gan Hui Cai, Ming Xing Li, Lan Lu, Ruby Lok Yi Chan, Jian Hao Wang and Chi Hin Cho
Affiliation:
Keywords: Cancer, colon, inflammation, vitamin D.
Abstract: Vitamin D, beyond its classical roles in the regulation of calcium and phosphorus homeostasis and bone metabolism, has been implicated in multiple pathological processes, including progression from inflammation to cancer development and also involvement in autoimmune diseases as well as cardiovascular disorders. In this review, we shall discuss the different roles of vitamin D and its therapeutic targets in different gastrointestinal diseases, focusing on colorectal cancer (CRC) and inflammatory bowel disease (IBD). To this end, vitamin D deficiency has been identified as a risk factor of CRC. On the other hand the active metabolite of vitamin D, 1, 25- dihydroxyvitamin D3 (1, 25(OH)2D3) has multiple anti-cancerous benefits including inhibition of proliferation, induction of apoptosis, promotion of differentiation and suppression of angiogenesis in tumors. In IBD, vitamin D is involved in the pathogenic process through the normalization of immune responses in the colon. With these experimental findings, well-designed and large-scale clinical trials are warranted to further define the therapeutic action of vitamin D in the prevention and/or treatment of IBD and further on CRC in humans.
Export Options
About this article
Cite this article as:
Cai Hui Gan, Li Xing Ming, Lu Lan, Yi Chan Lok Ruby, Wang Hao Jian and Cho Hin Chi, The Current Role and Therapeutic Targets of Vitamin D in Gastrointestinal Inflammation and Cancer, Current Pharmaceutical Design 2015; 21 (21) . https://dx.doi.org/10.2174/1381612821666150514103105
DOI https://dx.doi.org/10.2174/1381612821666150514103105 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Sinonasal Carcinoma: Updated Phenotypic and Molecular Characterization
Current Cancer Therapy Reviews Application of Reproductive Hormone Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology Anti-cancer Peptides from Ras-P21 and P53 Proteins
Current Pharmaceutical Design Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Gut Epithelial Lining Makes the First Move
Current Immunology Reviews (Discontinued) Four-Component Synthesis of 1,2-Dihydropyridine Derivatives and their Evaluation as Anticancer Agents
Medicinal Chemistry The Therapeutic Value of Natural Agents to Treat miRNA Targeted Breast Cancer in African-American and Caucasian-American Women
Current Drug Targets Recent Development of Small Molecule Glutaminase Inhibitors
Current Topics in Medicinal Chemistry Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Current Cancer Drug Targets Proteases and their Receptors as Mediators of Inflammation-Associated Colon Cancer
Current Pharmaceutical Design Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Connecting A Tumor to the Environment
Current Pharmaceutical Design Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases?
Current Medicinal Chemistry DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics Epigenetics of Aging
Current Genomics The Interaction of GLUT1 and FOXM1 Leads to a Poor Prognosis in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design